Heterobifunctional chimeric degraders are a class of ligands that recruit target proteins to E3 ubiquitin ligases to drive compound-dependent protein degradation. Advancing from initial chemical tools, protein degraders represent a mechanism of growing interest in drug discovery. Critical to the mechanism of action is the formation of a ternary complex between the target, degrader and E3 ligase to promote ubiquitination and subsequent degradation. However, limited insights into ternary complex structures exist, including a near absence of studies on one of the most widely co-opted E3s, cellular inhibitor of apoptosis 1 (cIAP1). In this work, we use a combination of biochemical, biophysical and structural studies to characterize degrader-mediated ternary complexes of Bruton’s tyrosine kinase and cIAP1. Our results reveal new insights from unique ternary complex structures and show that increased ternary complex stability or rigidity need not always correlate with increased degradation efficiency.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Structural coordinates from X-ray crystallography experiments have been deposited at RCSB with the following accession codes: 6W74 (cIAP1–BC5P binary structure), 6W7O (BTK–BCPyr–cIAP1 ternary structure) and 6W8I (BTK–BC5P–cIAP1 ternary structure). NMR data have been deposited to the Biological Magnetic Resonance Data Bank. Source data are provided with this paper.
Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1–cullin–F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554–8559 (2001).
Ohoka, N. et al. In vivo knockdown of pathogenic proteins via specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs). J. Biol. Chem. 292, 4556–4570 (2017).
Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611–617 (2015).
Sun, X. et al. A chemical approach for global protein knockdown from mice to non-human primates. Cell Discov. 5, 10 (2019).
Schneekloth, A. R., Pucheault, M., Tae, H. S. & Crews, C. M. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg. Med. Chem. Lett. 18, 5904–5908 (2008).
Mullard, A. First targeted protein degrader hits the clinic. Nat. Rev. Drug Discov. 18, 237–239 (2019).
Schapira, M., Calabrese, M. F., Bullock, A. N. & Crews, C. M. Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949–963 (2019).
Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755–763 (2015).
Nowak, R. P. et al. Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat. Chem. Biol. 14, 706–714 (2018).
Zorba, A. et al. Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc. Natl Acad. Sci. USA 115, E7285–E7292 (2018).
Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376–1381 (2015).
Farnaby, W. et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat. Chem. Biol. 15, 672–680 (2019).
Gadd, M. S. et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat. Chem. Biol. 13, 514–521 (2017).
Min, J.-H. et al. Structure of an HIF-1α–pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886–1889 (2002).
Zoppi, V. et al. Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel–Lindau (VHL) based dual degrader probe of BRD9 and BRD7. J. Med. Chem. 62, 699–726 (2019).
Peng, Y. et al. Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents. J. Med. Chem. 55, 106–114 (2012).
Sun, H., Lu, J., Liu, L., Yang, C.-Y. & Wang, S. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells. ACS Chem. Biol. 9, 994–1002 (2014).
Varfolomeev, E. et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131, 669–681 (2007).
Chessari, G. et al. Fragment-based drug discovery targeting inhibitor of apoptosis proteins: discovery of a non-alanine lead series with dual activity against cIAP1 and XIAP. J. Med. Chem. 58, 6574–6588 (2015).
Tamanini, E. et al. Discovery of a potent nonpeptidomimetic, small-molecule antagonist of cellular inhibitor of apoptosis protein 1 (cIAP1) and X-linked inhibitor of apoptosis protein (XIAP). J. Med. Chem. 60, 4611–4625 (2017).
Sun, H. et al. Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J. Med. Chem. 53, 6361–6367 (2010).
Ohoka, N. et al. Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation. J. Biol. Chem. 293, 6776–6790 (2018).
Okuhira, K. et al. Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein. FEBS Lett. 585, 1147–1152 (2011).
Itoh, Y., Ishikawa, M., Naito, M. & Hashimoto, Y. Protein knockdown using methyl bestatin–ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. J. Am. Chem. Soc. 132, 5820–5826 (2010).
Itoh, Y. et al. Development of target protein-selective degradation inducer for protein knockdown. Bioorg. Med. Chem. 19, 3229–3241 (2011).
Itoh, Y., Kitaguchi, R., Ishikawa, M., Naito, M. & Hashimoto, Y. Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. Bioorg. Med. Chem. 19, 6768–6778 (2011).
Demizu, Y. et al. Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy. Bioorg. Med. Chem. Lett. 22, 1793–1796 (2012).
Tinworth, C. P. et al. PROTAC-mediated degradation of Bruton’s tyrosine kinase is inhibited by covalent binding. ACS Chem. Biol. 14, 342–347 (2019).
Casillas, L. N., Harling, J. D. M., Afjal H., Smith, I. E. D. & Rackham, M. D. Preparation of PROTAC compounds conjugates comprising RIPK2 inhibitors, especially IAP binder linked RIPK2 inhibitors, for treating inflammations. International patent WO2017182418 A1 (2017).
Shibata, N. et al. Development of protein degradation inducers of oncogenic BCR–ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 108, 1657–1666 (2017).
Huang, H.-T. et al. A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader. Cell Chem. Biol. 25, 88–99 (2018).
Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32–42 (2013).
Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507–516 (2013).
Pan, Z. et al. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem 2, 58–61 (2007).
Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075–13080 (2010).
Buhimschi, A. D. et al. Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation. Biochemistry 57, 3564–3575 (2018).
Woyach, J. A. et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 2286–2294 (2014).
Sun, Y. et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res. 28, 779–781 (2018).
Borzilleri, R. M. P. et al. Preparation of peptide IAP antagonists for cancer treatment. International patent WO2014047024A1 (2013).
Feltham, R. et al. Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. J. Biol. Chem. 286, 17015–17028 (2011).
Horst, R., Horwich, A. L. & Wüthrich, K. Translational diffusion of macromolecular assemblies measured using transverse-relaxation-optimized pulsed field gradient NMR. J. Am. Chem. Soc. 133, 16354–16357 (2011).
Sekine, K. et al. Small molecules destabilize cIAP1 by activating auto-ubiquitylation. J. Biol. Chem. 283, 8961–8968 (2008).
Dueber, E. C. et al. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science 334, 376–380 (2011).
Lopez, J. et al. CARD-mediated autoinhibition of cIAP1’s E3 ligase activity suppresses cell proliferation and migration. Mol. Cell 42, 569–583 (2011).
Ciulli, A., Testa, A., Hughes, S. J., Lucas, X. & Wright, J. E. Structure-based design of a macrocyclic PROTAC. Angew. Chem. Int. Ed. Engl. https://doi.org/10.1002/anie.201914396 (2019).
Duda, D. M. et al. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 134, 995–1006 (2008).
Baek, K. et al. NEDD8 nucleates a multivalent cullin–RING–UBE2D ubiquitin ligation assembly. Nature 578, 461–466 (2020).
Mares, A. et al. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2. Commun. Biol. 3, 140 (2020).
Zhang, X. et al. Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur. J. Med. Chem. 199, 112397 (2020).
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
Condon, S. M. et al. Birinapant, a Smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J. Med. Chem. 57, 3666–3677 (2014).
Bender, A. T. et al. Ability of Bruton’s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling. Mol. Pharmacol. 91, 208 (2017).
Blanc, E. et al. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr. D Biol. Crystallogr. 60, 2210–2221 (2004).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).
Drummond, M. L. & Williams, C. I. In silico modeling of PROTAC-mediated ternary complexes: validation and application. J. Chem. Inf. Model. 59, 1634–1644 (2019).
Harder, E. et al. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J. Chem. Theory Comput. 12, 281–296 (2016).
Watts, K. S. et al. ConfGen: a conformational search method for efficient generation of bioactive conformers. J. Chem. Inf. Model. 50, 534–546 (2010).
Bax, A. & Grzesiek, S. Methodological advances in protein NMR. Acc. Chem. Res. 26, 131–138 (1993).
Bartels, C., Xia, T.-H, Billeter, M., Güntert, P. & Wüthrich, K. The program XEASY for computer-supported NMR spectral analysis of biological macromolecules. J. Biomol. NMR 6, 1–10 (1995).
Keller, R. Optimizing the Process of Nuclear Magnetic Resonance Spectrum Analysis and Computer Aided Resonance Assignment PhD thesis, ETH Zurich (2005).
We thank K. Fennell and P. Montanaro for expression of [15N13C]cIAP1Bir3 used in the pilot NMR experiments, J. Chang for the protein purification schemes of cIAP1Bir3 and biotinylated BTKKD and L. Byrnes and A. Varghese for SEC MALS troubleshooting and analysis. We also thank J. Knafels for crystal preparation before synchrotron shipment and J. Smith for the THP-1 cell culture and degradation protocols. BC5P synthesis was assisted by A. Davies. Compounds BC2P and BCPyr were synthesized by Wuxi PharmaTech. We also thank K. Farley, A. Ratnayake and T. Ryder for assistance with small-molecule NMR analysis. All individuals named are current or former members of Pfizer Worldwide Research and Development, Groton CT, USA.
All authors are current or former employees of Pfizer, Inc.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
a, Two representative replicate experiments (top and bottom) of dose dependent BTK degradation in THP1 cells and associated DC50 curve-fit. b, Schematic representation of 2-PEG ‘BC2P’ (2), with regions corresponding to BTK ligand (magenta), linker (black) and cIAP1 ligand (blue) indicated. c, Western blot analysis of dose dependent BTK degradation in THP1 cells by BC5P (left), BC2P (right) and associated DC50 curve-fit. The experiment was repeated for a total of 3 independent experiments with reproducible findings (d) Rescue of BC5P dependent degradation using a BTK ligand, and corresponding vinculin loading control with densiometric quantification shown on the left. The experiment was repeated for a total of 5 independent experiments with reproducible findings. Filled circles and hollow triangles represent untreated or BTK ligand treated samples, respectively. Error bars represent ± 1 standard deviation and these data are a result of n=5 independent experiments. Statistical analysis was performed using a two-sided student’s unpaired T Test where significance (*) a p value of 0.022 and 0.033 for 2.5 μM and 0.083 μM treatments, respectively.
Electron density difference map examining ternary complex Pose 2, with BC5P. Anisotropic data (left), and isotropic data (right) with 2Fo-Fc σ = 1.0.
a, Overlay of [15N,1H]-COSY spectra with15N13C cIAP1Bir3 as either apo (red) or an IAP-ligand binary complex (blue). b, [15N,1H]-HSQC spectrum of uniformly 15N,13C-enriched cIAP1Bir3 in complex with the IAP-ligand. Backbone resonance assignments are indicated by the one-letter amino acid code and the sequence number. The backbone cross-peaks of G46 and C62 are outside of the region shown. c, TRO-STE spectra of cIAP1Bir3/BC5P/BTKKD. The relative signal intensity ln(S/So) is plotted versus the square of the field gradient strength, \(G_D^2\). Green triangles and black squares represent data for the apo form of cIAP1Bir3 and for the cIAP1Bir3/BC5P/BTKKD ternary complex, respectively. Translational diffusion coefficients, Dt, as calculated from the diffusion data are indicated.
a, Electron density difference map examining the binary crystal structure of cIAP1Bir3 and BC5P. Density substantially weakens over the benzyl portion of the tetrahydroisoquinoline, thus preventing further modeling of the linker. Protein is omitted on the right panel for clarity. b, Protein-Ligand interactions between BC5P and cIAP1Bir3 in the binary crystal structure. Dashed lines indicate a set of polar interactions ≤ 3.5 Å in length.
a, Western blot image of in vitro ubiquitination of BTKKD by cIAP1BUCR1 in the presence of BC5P, or BCPyr. Quantification of mUb and pUb signal was done using ImageJ analysis (v220.127.116.11). b, Ternary complex assay sensorgram of a binary [cIAP1Bir3-BC5P] complex binding to BTKKD, and (c) [cIAP1Bir3-BCPyr] complex binding to BTKKD. For panel B, data was fit globally (left) or independently for Kon and Koff (right) yielding consistent affinity values.
Electron density for the BTKKD/BCPyr/cIAP1Bir3 ternary complex structure covering a portion of the protein-protein interface (proximal to BTKKD R487). Left and middle panels show map (2Fo-Fc contoured at σ = 1.0) for the two copies in the asymmetric unit. Panel on the right shows an overlay of the two copies with density omitted. R487 sidechain is modeled in different conformations in the two copies, projecting toward either one or both aspartic acids presented by cIAP1.
a, Top panel: Crystallographic pose of BTKKD (gray), cIAP1Bir3 (orange), and BCPyr (light orange). Bottom panel: Linker substitution modeled to generate Piperidine ‘BCPip’ (4) (purple). b, Schematic representation of BCPip, with regions corresponding to BTK ligand (Magenta), linker (Black) and IAP ligand (Blue) indicated. c, Ternary complex assay sensorgram of a binary [cIAP1BUCR1-BCPip] complex binding to BTKKD. d, Western blot analysis of dose dependent BTK degradation in THP1 cells by BCPip and associated DC50 curve-fit.
a, Native ESI Mass spectrometry showing the spectrum for monomeric cIAP1BUCR1 (Top Panel) or a spectrum for cIAP1BUCR1/ BC5P (Bottom Panel). A Distinct M/Z shift between cIAP1BUCR1 monomer (+) and cIAP1BUCR1 monomer after BC5P (‡) treatment is indicative of a single molecule of BC5P binding to the monomer. The dimer fraction (#) is comprised of 2 molecules of BC5P bound to 2 molecules of cIAP1BUCR1. These data demonstrate a 1:1 or 2:2 stoichiometry of BC5P for cIAP1BUCR1. b, Size Exclusion Chromatography Multi-Angle Light Scattering (SEC MALS) chromatograph of a cIAP1BUCR1/BC5P dimer (red), a lower concentration intermediate (blue), and a DMSO treated cIAP1BUCR1 monomer (black). Calculated molecular weights are shown as squares, change in refractive index (dRI) is shown as dotted lines, light scattering (LS) is shown as solid lines, and expected molecular weights are shown as dashed light blue lines. c, SEC MALS chromatograph of a cIAP1BUCR1/BCPyr dimer (red), and a cIAP1BUCR1/BCPyr/BTKKD dimer of ternary complexes (purple). Calculated molecular weights shown as squares, change in refractive index (dRI) is shown as dotted lines, light scattering (LS) is shown as solid lines, and expected molecular weights are shown as dashed light blue lines. This experiment was performed 3 times with reproducible results.
About this article
Cite this article
Schiemer, J., Horst, R., Meng, Y. et al. Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes. Nat Chem Biol 17, 152–160 (2021). https://doi.org/10.1038/s41589-020-00686-2
Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
RSC Chemical Biology (2021)
Drug Discovery Today: Technologies (2020)